|
(* indicates that article
is indexed in Medline) Allergies
& Asthma [back to top] Grubbe R, Adelglass JM, Casale TB, et al. Comparison of intranasal therapy with once-daily triamcinolone acetonide aerosol versus twice-daily beclomethasone dipropionate aqueous spray in perennial allergic rhinitis. *Holgate ST, Arshad H, Stryszak P, Harrison JE. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. J Allergy Clin Immunol. 2000;105:906-11. [view article] Lim JC. Asthma: evolution of treatment based on knowledge of etiology. RPR, Collegeville PA. *Lutsky BN, Schuller JL, Cerio R, et al. Comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of chronic allergic skin diseases in a pediatric population. Arzneimittelforschung. 1993;43(11):1196-9. [view article] *Roman IJ, Danzig MR. Loratadine. A review of recent finding in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine. Clin Rev Allergy. 1993:11(1):89-110 [view article] Shore ET, Baldinger S, Albino S, Russomanno J, Deshmukh V. The impact of propofol (Diprivan) in intubated patients with status asthmaticus. (Abstract). Suh DC. Gender differences in
chronic obstructive pulmonary disease: related visits, prescription, and
disposition practices.
Fishman WH. Weber M, ZIAC National Hypertension Trial Study Group. A contemporary look at beta-blocker/diuretic combination therapy: results of the ZIAC national hypertension trial. *Grayburn PA, Weiss JL, Hack TC, et al. Phase II multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal echocardiograms. J Am Coll Cardiol. 1998;32(1):230-236. [view article] Luscher TF. Endothelial dysfunction in atherosclerosis. Journal of Myocardial Ischemia. 1995;7(Suppl 1):15-20. [view article] Minimal occurrence of adverse effects with the
ionic contrast agent ISOVUE-370 in coronary arteriography and
ventriculography: role of risk factors.
Faria DT, Choucair M, Fiveson D, Effective management of venous stasis ulcers with human skin equivalent: a case study. Henry Ford Hospital, Detroit Michigan. *Eaglstein WH, Falange V. Tissue engineering and the development of Apligraf, a human skin equivalent. Clin Ther. 1997;19(5):894-905. [view article]
*Berardi RR. Safety and tolerability of
tegaserod in irritable bowel syndrome management. J Am Pharm Assoc. 2004;44(1):41-51.
[view article] Immunology / Rheumatology [back to top] *Dreiser RL. A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis. Rheumatol Int. 1993;13(2 Suppl):S13–8. [view article] Fleischmann R, Kivitz AJ, Franklin C, et al. A randomized, double-blind, placebo-controlled, sequential dose study of the safety of apratastat (TMI-005), a novel oral dual inhibitor of TNF-a-converting enzyme/metaloproteinase, in patients with rheumatoid arthritis on a background of methotrexate. 2005 *Munschauer FE, Stuart WH. Rationale for early treatment with interferon beta-1a in remitting-relapsing multiple sclerosis. Clin Ther. 1997;19(5)868-82. [view article] A randomized, double-blind, placebo-controlled sequential dose study of the safety of apratastat, a novel oral dual inhibitor of TNF-alpha-converting enzyme/metalloproteinase, in patients with rheumatoid arthritis on a background of methotrexate.
Brook I, Gooch WM, Jenkins SG, et al. Medical management of acute
bacterial sinusitis. Ann Otol Rhinol Laryngol Suppl. 2000;109(5):2-20. [view article] Gonik B. Strategies for fostering
HPV vaccine acceptance. Inf Dis Obstet Gynecol. 2006:1-4. [view
article] *Ji A J, Saunders J P, Nandan D, et al. A novel antibiotic bone assay by liquid chromatography/tandem mass spectrometry for quantitation of tigecycline in rat bone. J Pharm Biomed Analysis. 2007;44(4)970-979. [view article] *Ji AJ, Saunders JP, Amorusi P, et al. A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS. J Pharm Biomed Anal. 2008;48(3):866-875. [view article] Lisbon A. Dopexamine, dobutamine, dopamine increase splanchnic blood flow: what is the evidence? *Stengel F,
Robles-Soto M, Galimberti R, Suchil P. Fluconazole versus ketoconazole in the
treatment of dermatophytoses and cutaneous candidiasis. Int J Dermatol. 1994;33(10):726-729.
[view article] Toney JF. Randomized, double-blind
comparison of oral cefpodoxime proxetil with parenteral ceftriaxone in
community-acquired pneumonia. James A Haley Veterans’ Hospital, Tampa FL.
Linder J. A sample preparation system for enhanced clarity in Pap test analysis. American Clinical Laboratory. 1996:12-13. [view article]
*Cohn MA. Effects of zolpidem, codeine phosphate and placebo on respiration. A double-blind, crossover study in volunteers. Drug Safety. 1993;9(4):312-319. [view article] Goodman A, Vollmer T, Blight A, Marinucci. Steady-state pharmacokinetics of orally administered fampridine (4-aminopyridine) sustained release tablets in patients with multiple sclerosis. In Press. Goodman A, Vollmer T, Marinucci L. Pharmacokinetics of single administration, escalating doses of fampridine sustained release tablets in subjects with multiple sclerosis. In Press. *Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry. 1993:54(3):13-17. [view article] *Mitler MM. Nonselective and selective benzodiazepine receptor agonists—where are we today? Sleep. 2000;23(Suppl 1).S39-S47. [view article] Patat A. Safety, tolerability,
pharmacokinetics, and pharmacodynamics of ascending single and multiple oral
doses of SRA-333, a serotonin 1a receptor antagonist, in healthy subjects.
2005. *Poduslo SE, Miller K, Piasecki B [nee Rinehart B], McKhann GM.
Isolation of cells from normal and abnormal brain. Trans Am Neurol Assoc.
1977;102:13-5. Poduslo SE, Miller K, Piasecki B [nee Rinehart B], McKhann GM.
Metabolic properties of maintained oligodendroglia. Trans Am Soc Neurochem.
1997:8. Poduslo SE, Miller K, Piasecki B [nee Rinehart B], McKhann GM. In vitro
studies with bulk-isolated oligodendroglia maintained in culture. Sixth
International Meeting of the International Society for Neurochemistry,
Copenhagen, Denmark (1977). Poduslo SE, Miller K, Piasecki B[nee Rinehart B], McKhann GM. Do oligodendroglia produce myelin in vitro? Satellite Symposium on Myelination and Demyelination. Helsinki, Finland (1977). *Stein LI. A system approach to reducing relapse in schizophrenia. . J Clin Psychiatry. 1993:54(3):7-17. [view article] Wasterlain Claude, MD. Mechanisms of action of novel antiepileptic drugs. Pharmacology and toxicology of antiepileptic drugs: lessons from animal models. Safety, tolerability, pharmacokinetic, and
pharmacodynamic studies
Wadden T. Methods for preventing weight gain after weight loss. Hospital University of Pennsylvania. Nursing approaches to counseling
the obese patient Oncology [back to top] Mangan, K. Cardiac amyloidosis and severe congestive heart failure treated with high-dose melphalan and autologous peripheral blood stem cell transplantation. Temple University School of Medicine. Philadelphia PA. [view article] Miguel JS. Characteristics, pathogenesis, and novel treatment for multiple myeloma. J Natl Compr Canc Netw. 2004;2(Suppl 4):S1-S4. [view article] DeMartino GN. Proteasome inhibition: mechanism of action. J Natl Compr Canc Netw. 2004;2(Suppl 4):S5-S9. [view article] Stadtmauer E. Proteasome inhibition for treatment of multiple myeloma: clinical update. J Natl Compr Canc Netw. 2004;2(Suppl 4):S10-S15. [view article] Orlowski R. Bortezomib in combination with other therapies for the treatment of multiple myeloma. J Natl Compr Canc Netw. 2004;2(Suppl 4):S16-S20. [view article] O’Connor O, Wright J, Moskowitz CH, et al. Promising
activity of the proteasome inhibitor bortezomib (VELCADE®) in the
treatment of indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: ASH
poster session 517-II. J Natl Compr Canc Netw. 2004;2(Suppl
4):S21-S22. [view
article] Mitsiades CS. Molecular profiles
of proteasome inhibition in plasma cell dyscrasias. J Natl Compr Canc Netw.
2004;2(Suppl 4):S23-S29. [view
article] Role of anthracyclines as adjuvant chemotherapy in patients with early breast cancer. Re-analysis of Early Breast Cancer Trialists Collaborative Group (EBCTCG) data. 2003. Ophthalmology [back to top] *Hartenbaum D. The efficacy of dorzolamide, a
topical carbonic anhydrase inhibitor, in combination with timolol in the
treatment of patients with open-angle glaucoma and ocular hypertension. Clin
Ther. 1996;18(3):460-465. [view article]
Long-term safety of etodolac SR (Lodine SR) in rheumatoid and osteoarthritis Dorsam J, Drehmer I, Brkovic D, Wigand J, Carl S, Staehler G. Analgesic effect of diclofenac and dipyrone in renal colic. Department of Urology, University of Heidelberg, Germany. Vilensky William, RPh, DO. Pharmacists role in pain management: focus on agonist/antagonist opioids. UMDNJ, Robert Woods Johnson Medical School, NJ. Cytotec open-label clinical experience trial in
patients with arthritis.
Martinez
FJ, Raczek AE, Seifer FD, et al. Development and Initial Validation Women’s Health [back to top] *Davie JE, Walling MR, Mansour DJ, et al. Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther. 1996,18(1):150-159. Bromhan D, Walling MR, Mansour DJA, Davie JE, Kishen M, Fowler P, et al. One-year clinical experience with the Norplant contraceptive system in the United Kingdom. *Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998;43(1):24-27. Kjos SJ, MD. Contraception for women at risk: a case for the IUD. Contraception and Preconception care. Dialogues in Contraception. 2004.
Implantable Contraceptives: Implanon. Dialogues in Contraception. 2004. Safety
and efficacy of low-dose postmenopausal hormonal therapy. 2003.
|
||||||
|
|
||||||
